Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BioAge Labs, Inc.

Get SEC filing alerts via email and in your feed for BioAge Labs, Inc.

BIOA

BioAge Labs, Inc.

About BioAge Labs, Inc.

BioAge Labs, Inc. is a biopharmaceutical company focused on developing therapies for metabolic diseases by targeting the biology of human aging. Its platform leverages longitudinal human datasets and multi-omic profiling to identify novel targets like NLRP3 and apelin. The company develops oral, brain-penetrant small molecules and collaborates with major pharma firms to create innovative treatments for obesity and age-related conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BioAge Labs, Inc.

1
1
BioAge Labs, Inc. BioAge Labs Reports 91% Increase in Collaboration Revenue, Faces Rising Operating Losses in Q1 2026

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
BioAge Labs, Inc. BioAge Labs Reports $80.6 Million Net Loss for 2025, Advances BGE-102 in Clinical Trials

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
BioAge Labs, Inc. BioAge Labs Reports Q3 2025 Financial Results with $2.1M Collaboration Revenue

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BioAge Labs, Inc. BioAge Labs Reports $2.4 Million Collaboration Revenue and $21.6 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BioAge Labs, Inc. BioAge Labs Reports Q1 2025 Financial Results with $1.5M Collaboration Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments